JAGSNPHARM Share Price Target 2027

CAGR-based price projection for Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) targeting 2027, derived from official NSE exchange closing prices.

Bear Case (8.0% CAGR)
Rs 250
2027 Target
Base Case (20.1% CAGR)
Rs 278
2027 Target
Bull Case (57.5% CAGR)
Rs 365
2027 Target

Current Market Snapshot

CMP: Rs 231.73
52W High: Rs 243.97
52W Low: Rs 185.42
1Y CAGR: 44.3%
3Y CAGR: 20.1%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 250 Rs 278 Rs 365

Other JAGSNPHARM Price Targets

2025 2026 2028 2030 2035 2040 2050

Frequently Asked Questions

What is the JAGSNPHARM share price target for 2027?

Based on historical growth analysis, the JAGSNPHARM share price target for 2027 ranges from Rs 250 (conservative) to Rs 278 (base case) to Rs 365 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of JAGSNPHARM?

The current market price of JAGSNPHARM (Jagsonpal Pharmaceuticals Limited) is Rs 231.73. The 52-week high is Rs 243.97 and 52-week low is Rs 185.42.

Is JAGSNPHARM a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for JAGSNPHARM price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 8.0% CAGR), Base (20.1% CAGR), and Bull (optimistic at 57.5% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.